Latest Insider Transactions at Heron Therapeutics, Inc. (HRTX)
This section provides a real-time view of insider transactions for Heron Therapeutics, Inc. (HRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HERON THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HERON THERAPEUTICS, INC. 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+22.07%
|
-
|
|
Sep 21
2021
|
Craig A Johnson |
SELL
Open market or private sale
|
Direct |
250
-7.49%
|
$3,000
$12.3 P/Share
|
|
Sep 21
2021
|
Waage Christian |
SELL
Open market or private sale
|
Direct |
300
-7.89%
|
$3,600
$12.31 P/Share
|
|
Jul 13
2021
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-15.01%
|
$5,629
$13.48 P/Share
|
|
Jul 13
2021
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+30.24%
|
-
|
|
Jul 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
191
-1.36%
|
$2,483
$13.48 P/Share
|
|
Jul 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
552
+3.79%
|
-
|
|
Jul 13
2021
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-1.91%
|
$5,629
$13.48 P/Share
|
|
Jul 13
2021
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+5.23%
|
-
|
|
Jul 13
2021
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
963
-0.96%
|
$12,519
$13.48 P/Share
|
|
Jul 13
2021
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,645
+3.5%
|
-
|
|
Jul 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-12.04%
|
$5,629
$13.48 P/Share
|
|
Jul 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+25.79%
|
-
|
|
Jun 21
2021
|
Craig A Johnson |
SELL
Open market or private sale
|
Direct |
250
-6.96%
|
$3,750
$15.2 P/Share
|
|
Jun 21
2021
|
Waage Christian |
SELL
Open market or private sale
|
Direct |
300
-7.32%
|
$4,500
$15.2 P/Share
|
|
May 03
2021
|
Kimberly Manhard EVP, Drug Development |
SELL
Open market or private sale
|
Direct |
1,529
-48.34%
|
$25,993
$17.66 P/Share
|
|
Apr 30
2021
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Other acquisition or disposition
|
Direct |
1,530
+10.2%
|
$19,890
$13.9 P/Share
|
|
Apr 30
2021
|
John Poyhonen President & CCO |
BUY
Other acquisition or disposition
|
Direct |
971
+4.34%
|
$12,623
$13.9 P/Share
|
|
Apr 30
2021
|
Barry D Quart Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
1,529
+1.56%
|
$19,877
$13.9 P/Share
|
|
Apr 30
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Other acquisition or disposition
|
Direct |
1,530
+39.46%
|
$19,890
$13.9 P/Share
|
|
Apr 30
2021
|
Kimberly Manhard EVP, Drug Development |
BUY
Other acquisition or disposition
|
Direct |
1,529
+32.59%
|
$19,877
$13.9 P/Share
|
|
Apr 15
2021
|
Waage Christian |
SELL
Open market or private sale
|
Direct |
300
-6.82%
|
$5,100
$17.51 P/Share
|
|
Apr 13
2021
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-20.95%
|
$6,928
$16.66 P/Share
|
|
Apr 13
2021
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+37.68%
|
-
|
|
Apr 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
191
-1.57%
|
$3,056
$16.66 P/Share
|
|
Apr 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
552
+4.35%
|
-
|
|
Apr 13
2021
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-2.08%
|
$6,928
$16.66 P/Share
|
|
Apr 13
2021
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+5.66%
|
-
|
|
Apr 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-34.64%
|
$6,928
$16.66 P/Share
|
|
Apr 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+50.0%
|
-
|
|
Apr 13
2021
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
963
-1.0%
|
$15,408
$16.66 P/Share
|
|
Apr 13
2021
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,646
+3.65%
|
-
|
|
Apr 06
2021
|
Craig A Johnson |
SELL
Open market or private sale
|
Direct |
250
-6.51%
|
$4,250
$17.22 P/Share
|
|
Jan 14
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
827
-100.0%
|
$14,886
$18.09 P/Share
|
|
Jan 13
2021
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-34.64%
|
$7,794
$18.16 P/Share
|
|
Jan 13
2021
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+50.0%
|
-
|
|
Jan 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
227
-1.92%
|
$4,086
$18.16 P/Share
|
|
Jan 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
552
+4.46%
|
-
|
|
Jan 13
2021
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-2.16%
|
$7,794
$18.16 P/Share
|
|
Jan 13
2021
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+5.87%
|
-
|
|
Jan 13
2021
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
963
-1.04%
|
$17,334
$18.16 P/Share
|
|
Jan 13
2021
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,646
+3.78%
|
-
|
|
Jan 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
423
-33.84%
|
$7,614
$18.16 P/Share
|
|
Jan 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+50.0%
|
-
|
|
Jan 08
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,571
-100.0%
|
$67,849
$19.66 P/Share
|
|
Dec 22
2020
|
Kimberly Manhard EVP, Drug Development |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$200,000
$20.0 P/Share
|
|
Dec 22
2020
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$130,000
$13.0 P/Share
|
|
Dec 21
2020
|
Stephen Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+50.0%
|
-
|
|
Dec 21
2020
|
Craig A Johnson |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+43.86%
|
-
|
|
Dec 21
2020
|
Waage Christian |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+40.54%
|
-
|